Skip to main content
SpringerLink
Log in
Book cover

Resistance to Targeted Therapies Against Adult Brain Cancers pp 175–198Cite as

Imaging Targeted Therapy Response and Resistance in Glioblastoma

  • Chapter
  • First Online:

  • 497 Accesses

Part of the book series: Resistance to Targeted Anti-Cancer Therapeutics ((RTACT))

Abstract

Glioblastoma (GBM) is the most common and most malignant tumour of the central nervous system. Despite recent advances in understanding the biology of GBM, the disease still remains in desperate need of effective treatment options resulting in long-term improvements in overall patient survival. Molecularly targeted therapies, anti-angiogenic therapy and immunotherapy are promising avenues under investigation as future therapeutic options. Molecular imaging (MI) is an essential tool in the development of these targeted treatments, both preclinically and clinically. MI facilitates the preclinical study and interrogation of potential therapies. MI further supports non-invasive, longitudinal monitoring of therapy response and allows the study of emergence of treatment resistance via an imaging-guided therapeutic approach.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Abbreviations

ADC:

Apparent diffusion coefficient

BBB:

Blood–brain barrier

BOLD-fMRI:

Blood-oxygen-level-dependent contrast fMRI

Cho:

Choline

Cr:

Creatine/phosphocreatine

CT:

Computed tomography

DKI:

Diffusion kurtosis imaging

DSC-MR:

Dynamic-susceptibility weighted contrast MR

DTI:

Diffusion tensor imaging

EGFR:

Epidermal growth factor receptor

FA:

Fractional anisotropy

FLI:

Fluorescence imaging

GLUTs:

Glucose transporters

Lac:

Lactate

LGG:

Low grade glioma

Lip:

Lipids

mI:

Myoinositol

MI:

Molecular imaging

MRI:

Magnetic resonance imaging

MRS:

MR spectroscopy

NAA:

N-acetyl aspartate

PET:

Positron emission tomography

rCBF:

Relative cerebral blood flow

rCBV:

Relative cerebral blood volume

SPECT:

Single photon emission computed tomography

TT:

Transit time

References

  1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114(2):97–109.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M, Ancukiewicz M, Mrugala MM, Plotkin S, Drappatz J, Louis DN, Ivy P, Scadden DT, Benner T, Loeffler JS, Wen PY, Jain RK. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007;11(1):83–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O’Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM, Hayes DN; Cancer Genome Atlas Research Network. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. (2010);17(1):98–110.

    Google Scholar 

  4. Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ; ALA-Glioma Study Group. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol (2006);7(5):392–401.

    Google Scholar 

  5. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. (2005);352(10):987–96.

    Google Scholar 

  6. Delgado-Lopez PD, Corrales-Garcia EM. Survival in glioblastoma: a review on the impact of treatment modalities. Clin Transl Oncol. (2016).

    Google Scholar 

  7. Papathanassiou D, Liehn JC. The growing development of multimodality imaging in oncology. Crit Rev Oncol Hematol. 2008;68(1):60–5.

    Article  PubMed  Google Scholar 

  8. Yankeelov TE, Abramson RG, Quarles CC. Quantitative multimodality imaging in cancer research and therapy. Nat Rev Clin Oncol. 2014;11(11):670–80.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Corroyer-Dulmont A, Peres EA, Gerault AN, Savina A, Bouquet F, Divoux D, Toutain J, Ibazizene M, MacKenzie ET, Barre L, Bernaudin M, Petit E, Valable S. Multimodal imaging based on MRI and PET reveals [(18)F]FLT PET as a specific and early indicator of treatment efficacy in a preclinical model of recurrent glioblastoma. Eur J Nucl Med Mol Imaging. 2016;43(4):682–94.

    Article  CAS  PubMed  Google Scholar 

  10. Ward KM, Aletras AH, Balaban RS. A new class of contrast agents for MRI based on proton chemical exchange dependent saturation transfer (CEST). J Magn Reson. 2000;143(1):79–87.

    Article  CAS  PubMed  Google Scholar 

  11. Guldris N, Argibay B, Kolen’ko YV, Carbo-Argibay E, Sobrino T, Campos F, Salonen LM, Banobre-Lopez M, Castillo J, Rivas J. Influence of the separation procedure on the properties of magnetic nanoparticles: gaining in vitro stability and T1-T2 magnetic resonance imaging performance. J Colloid Interface Sci. 2016;472:229–36.

    Article  CAS  PubMed  Google Scholar 

  12. Dhermain FG, Hau P, Lanfermann H, Jacobs AH, van den Bent MJ. Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas. Lancet Neurol. 2010;9(9):906–20.

    Article  PubMed  Google Scholar 

  13. Kao HW, Chiang SW, Chung HW, Tsai FY, Chen CY. Advanced MR imaging of gliomas: an update. Biomed Res Int. 2013;2013:970586.

    PubMed  PubMed Central  Google Scholar 

  14. Massaad CA, Pautler RG. Manganese-enhanced magnetic resonance imaging (MEMRI). Methods Mol Biol. 2011;711:145–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Shiroishi MS, Castellazzi G, Boxerman JL, D’Amore F, Essig M, Nguyen TB, Provenzale JM, Enterline DS, Anzalone N, Dorfler A, Rovira A, Wintermark M, Law M. Principles of T2 *-weighted dynamic susceptibility contrast MRI technique in brain tumor imaging. J Magn Reson Imaging. 2015;41(2):296–313.

    Article  PubMed  Google Scholar 

  16. Kang Y, Choi SH, Kim YJ, Kim KG, Sohn CH, Kim JH, Yun TJ, Chang KH. Gliomas: histogram analysis of apparent diffusion coefficient maps with standard- or high-b-value diffusion-weighted MR imaging--correlation with tumor grade. Radiology. 2011;261(3):882–90.

    Article  PubMed  Google Scholar 

  17. Murakami R, Hirai T, Sugahara T, Fukuoka H, Toya R, Nishimura S, Kitajima M, Okuda T, Nakamura H, Oya N, Kuratsu J, Yamashita Y. Grading astrocytic tumors by using apparent diffusion coefficient parameters: superiority of a one- versus two-parameter pilot method. Radiology. 2009;251(3):838–45.

    Article  PubMed  Google Scholar 

  18. Kono K, Inoue Y, Nakayama K, Shakudo M, Morino M, Ohata K, Wakasa K, Yamada R. The role of diffusion-weighted imaging in patients with brain tumors. AJNR Am J Neuroradiol. 2001;22(6):1081–8.

    CAS  PubMed  Google Scholar 

  19. Huisman TAGM. Diffusion-weighted and diffusion tensor imaging of the brain, made easy. Cancer Imaging. 2010;10(1A):S163–71.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Van Cauter S, Veraart J, Sijbers J, Peeters RR, Himmelreich U, De Keyzer F, Van Gool SW, Van Calenbergh F, De Vleeschouwer S, Van Hecke W, Sunaert S. Gliomas: diffusion kurtosis MR imaging in grading. Radiology. 2012;263(2):492–501.

    Article  PubMed  Google Scholar 

  21. Steven AJ, Zhuo J, Melhem ER. Diffusion kurtosis imaging: an emerging technique for evaluating the microstructural environment of the brain. AJR Am J Roentgenol. 2014;202(1):W26–33.

    Article  PubMed  Google Scholar 

  22. Ogawa S, Lee TM, Kay AR, Tank DW. Brain magnetic resonance imaging with contrast dependent on blood oxygenation. Proc Natl Acad Sci U S A. 1990;87(24):9868–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Mendichovszky I, Jackson A. Imaging hypoxia in gliomas. Br J Radiol. (2011);84 Spec No 2:S145–58.

    Google Scholar 

  24. Lucidarme O, Kono Y, Corbeil J, Choi SH, Golmard JL, Varner J, Mattrey RF. Angiogenesis: noninvasive quantitative assessment with contrast-enhanced functional US in murine model. Radiology. 2006;239(3):730–9.

    Article  PubMed  Google Scholar 

  25. Hande AH, Gadbail AR, Sonone AM, Chaudhary MS, Wadhwan V, Nikam A. Comparative analysis of tumour angiogenesis in solid multicystic and unicystic ameloblastoma by using CD 105 (endoglin). Arch Oral Biol. 2011;56(12):1635–40.

    Article  PubMed  Google Scholar 

  26. Essock-Burns E, Lupo JM, Cha S, Polley MY, Butowski NA, Chang SM, Nelson SJ. Assessment of perfusion MRI-derived parameters in evaluating and predicting response to antiangiogenic therapy in patients with newly diagnosed glioblastoma. Neuro Oncol. 2011;13(1):119–31.

    Article  PubMed  Google Scholar 

  27. Fan G. Comments and controversies: magnetic resonance spectroscopy and gliomas. Cancer Imaging. 2006;6:113–5.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Bulik M, Jancalek R, Vanicek J, Skoch A, Mechl M. Potential of MR spectroscopy for assessment of glioma grading. Clin Neurol Neurosurg. 2013;115(2):146–53.

    Article  PubMed  Google Scholar 

  29. Hamans B, Navis AC, Wright A, Wesseling P, Heerschap A, Leenders W. Multivoxel (1)H MR spectroscopy is superior to contrast-enhanced MRI for response assessment after anti-angiogenic treatment of orthotopic human glioma xenografts and provides handles for metabolic targeting. Neuro Oncol. 2013;15(12):1615–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Barker 2nd FG, Davis RL, Chang SM, Prados MD. Necrosis as a prognostic factor in glioblastoma multiforme. Cancer. 1996;77(6):1161–6.

    Article  PubMed  Google Scholar 

  31. Rock JP, Scarpace L, Hearshen D, Gutierrez J, Fisher JL, Rosenblum M, Mikkelsen T. Associations among magnetic resonance spectroscopy, apparent diffusion coefficients, and image-guided histopathology with special attention to radiation necrosis. Neurosurgery. 2004;54(5):1111–7. discussion 1117-1119.

    Article  PubMed  Google Scholar 

  32. Ahmad Sarji S. Physiological uptake in FDG PET simulating disease. Biomed Imaging Interv J. 2006;2(4), e59.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Galldiks N, Ullrich R, Schroeter M, Fink GR, Jacobs AH, Kracht LW. Volumetry of [(11)C]-methionine PET uptake and MRI contrast enhancement in patients with recurrent glioblastoma multiforme. Eur J Nucl Med Mol Imaging. 2010;37(1):84–92.

    Article  PubMed  Google Scholar 

  34. Jacobs AH, Thomas A, Kracht LW, Li H, Dittmar C, Garlip G, Galldiks N, Klein JC, Sobesky J, Hilker R, Vollmar S, Herholz K, Wienhard K, Heiss WD. 18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors. J Nucl Med. 2005;46(12):1948–58.

    CAS  PubMed  Google Scholar 

  35. Ullrich RT, Kracht L, Brunn A, Herholz K, Frommolt P, Miletic H, Deckert M, Heiss WD, Jacobs AH. Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients with glioma. J Nucl Med. 2009;50(12):1962–8.

    Article  PubMed  Google Scholar 

  36. Hutterer M, Nowosielski M, Putzer D, Jansen NL, Seiz M, Schocke M, McCoy M, Gobel G, la Fougere C, Virgolini IJ, Trinka E, Jacobs AH, Stockhammer G. [18F]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma. Neuro Oncol. 2013;15(3):341–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Nowosielski M, DiFranco MD, Putzer D, Seiz M, Recheis W, Jacobs AH, Stockhammer G, Hutterer M. An intra-individual comparison of MRI, [18F]-FET and [18F]-FLT PET in patients with high-grade gliomas. PLoS One. 2014;9(4), e95830.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Chandrasekaran S, Hollander A, Xu X, Benci JL, Davis JJ, Dorsey JF, Kao G. 18F-fluorothymidine-pet imaging of glioblastoma multiforme: effects of radiation therapy on radiotracer uptake and molecular biomarker patterns. ScientificWorldJournal. 2013;2013:796029.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Jacobs AH, Rueger MA, Winkeler A, Li H, Vollmar S, Waerzeggers Y, Rueckriem B, Kummer C, Dittmar C, Klein M, Heneka MT, Herrlinger U, Fraefel C, Graf R, Wienhard K, Heiss WD. Imaging-guided gene therapy of experimental gliomas. Cancer Res. 2007;67(4):1706–15.

    Article  CAS  PubMed  Google Scholar 

  40. Ullrich R, Backes H, Li H, Kracht L, Miletic H, Kesper K, Neumaier B, Heiss WD, Wienhard K, Jacobs AH. Glioma proliferation as assessed by 3′-fluoro-3′-deoxy-L-thymidine positron emission tomography in patients with newly diagnosed high-grade glioma. Clin Cancer Res. 2008;14(7):2049–55.

    Article  CAS  PubMed  Google Scholar 

  41. Rueger MA, Ameli M, Li H, Winkeler A, Rueckriem B, Vollmar S, Galldiks N, Hesselmann V, Fraefel C, Wienhard K, Heiss WD, Jacobs AH. [18F]FLT PET for non-invasive monitoring of early response to gene therapy in experimental gliomas. Mol Imaging Biol. 2011;13(3):547–57.

    Article  PubMed  Google Scholar 

  42. Viel T, Schelhaas S, Wagner S, Wachsmuth L, Schwegmann K, Kuhlmann M, Faber C, Kopka K, Schafers M, Jacobs AH. Early assessment of the efficacy of temozolomide chemotherapy in experimental glioblastoma using [18F]FLT-PET imaging. PLoS One. 2013;8(7), e67911.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Kato T, Shinoda J, Nakayama N, Miwa K, Okumura A, Yano H, Yoshimura S, Maruyama T, Muragaki Y, Iwama T. Metabolic assessment of gliomas using 11C-methionine, [18F] fluorodeoxyglucose, and 11C-choline positron-emission tomography. AJNR Am J Neuroradiol. 2008;29(6):1176–82.

    Article  CAS  PubMed  Google Scholar 

  44. Chen X, Park R, Shahinian AH, Tohme M, Khankaldyyan V, Bozorgzadeh MH, Bading JR, Moats R, Laug WE, Conti PS. 18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis. Nucl Med Biol. 2004;31(2):179–89.

    Article  CAS  PubMed  Google Scholar 

  45. Langen KJ, Pauleit D, Coenen HH. 3-[(123)I]Iodo-alpha-methyl-L-tyrosine: uptake mechanisms and clinical applications. Nucl Med Biol. 2002;29(6):625–31.

    Article  CAS  PubMed  Google Scholar 

  46. Dinca EB, Sarkaria JN, Schroeder MA, Carlson BL, Voicu R, Gupta N, Berger MS, James CD. Bioluminescence monitoring of intracranial glioblastoma xenograft: response to primary and salvage temozolomide therapy. J Neurosurg. 2007;107(3):610–6.

    Article  CAS  PubMed  Google Scholar 

  47. Yahyanejad S, Granton PV, Lieuwes NG, Gilmour L, Dubois L, Theys J, Chalmers AJ, Verhaegen F, Vooijs M. Complementary use of bioluminescence imaging and contrast-enhanced micro-computed tomography in an orthotopic brain tumor model. Mol Imaging. (2014);13. doi:10.2310/7290.2014.00038.

    Google Scholar 

  48. Luwor RB, Stylli SS, Kaye AH. Using bioluminescence imaging in glioma research. J Clin Neurosci. 2015;22(5):779–84.

    Article  PubMed  Google Scholar 

  49. O’Neill K, Lyons SK, Gallagher WM, Curran KM, Byrne AT. Bioluminescent imaging: a critical tool in pre-clinical oncology research. J Pathol. 2010;220(3):317–27.

    PubMed  Google Scholar 

  50. Hsu AR, Hou LC, Veeravagu A, Greve JM, Vogel H, Tse V, Chen X. In vivo near-infrared fluorescence imaging of integrin alphavbeta3 in an orthotopic glioblastoma model. Mol Imaging Biol. 2006;8(6):315–23.

    Article  PubMed  Google Scholar 

  51. Seystahl K, Wick W, Weller M. Therapeutic options in recurrent glioblastoma-an update. Crit Rev Oncol Hematol. 2016;99:389–408.

    Article  PubMed  Google Scholar 

  52. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997–1003.

    Article  CAS  PubMed  Google Scholar 

  53. Munoz JL, Rodriguez-Cruz V, Greco SJ, Ramkissoon SH, Ligon KL, Rameshwar P. Temozolomide resistance in glioblastoma cells occurs partly through epidermal growth factor receptor-mediated induction of connexin 43. Cell Death Dis. 2014;5, e1145.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Chi AS, Sorensen AG, Jain RK, Batchelor TT. Angiogenesis as a therapeutic target in malignant gliomas. Oncologist. 2009;14(6):621–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Kargiotis O, Rao JS, Kyritsis AP. Mechanisms of angiogenesis in gliomas. J Neurooncol. 2006;78(3):281–93.

    Article  CAS  PubMed  Google Scholar 

  56. Huettner C, Paulus W, Roggendorf W. Messenger RNA expression of the immunosuppressive cytokine IL-10 in human gliomas. Am J Pathol. 1995;146(2):317–22.

    CAS  PubMed  PubMed Central  Google Scholar 

  57. Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, Ciampa AS, Ebbeling LG, Levy B, Drappatz J, Kesari S, Wen PY. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology. 2008;70(10):779–87.

    Article  CAS  PubMed  Google Scholar 

  58. Viel T, Talasila KM, Monfared P, Wang J, Jikeli JF, Waerzeggers Y, Neumaier B, Backes H, Brekka N, Thorsen F, Stieber D, Niclou SP, Winkeler A, Tavitian B, Hoehn M, Bjerkvig R, Miletic H, Jacobs AH. Analysis of the growth dynamics of angiogenesis-dependent and -independent experimental glioblastomas by multimodal small-animal PET and MRI. J Nucl Med. 2012;53(7):1135–45.

    Article  CAS  PubMed  Google Scholar 

  59. Sugahara T, Korogi Y, Kochi M, Ikushima I, Hirai T, Okuda T, Shigematsu Y, Liang L, Ge Y, Ushio Y, Takahashi M. Correlation of MR imaging-determined cerebral blood volume maps with histologic and angiographic determination of vascularity of gliomas. AJR Am J Roentgenol. 1998;171(6):1479–86.

    Article  CAS  PubMed  Google Scholar 

  60. Jahangiri A, De Lay M, Miller LM, Carbonell WS, Hu YL, Lu K, Tom MW, Paquette J, Tokuyasu TA, Tsao S, Marshall R, Perry A, Bjorgan KM, Chaumeil MM, Ronen SM, Bergers G, Aghi MK. Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance. Clin Cancer Res. 2013;19(7):1773–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med. 2003;9(6):677–84.

    Article  CAS  PubMed  Google Scholar 

  62. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008;8(8):592–603.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, Gonzalez-Baron M. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev. 2004;30(2):193–204.

    Article  PubMed  Google Scholar 

  64. Gallia GL, Rand V, Siu IM, Eberhart CG, James CD, Marie SK, Oba-Shinjo SM, Carlotti CG, Caballero OL, Simpson AJ, Brock MV, Massion PP, Carson Sr BS, Riggins GJ. PIK3CA gene mutations in pediatric and adult glioblastoma multiforme. Mol Cancer Res. 2006;4(10):709–14.

    Article  CAS  PubMed  Google Scholar 

  65. Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, Beroukhim R, Bernard B, Wu CJ, Genovese G, Shmulevich I, Barnholtz-Sloan J, Zou L, Vegesna R, Shukla SA, Ciriello G, Yung WK, Zhang W, Sougnez C, Mikkelsen T, Aldape K, Bigner DD, Van Meir EG, Prados M, Sloan A, Black KL, Eschbacher J, Finocchiaro G, Friedman W, Andrews DW, Guha A, Iacocca M, O’Neill BP, Foltz G, Myers J, Weisenberger DJ, Penny R, Kucherlapati R, Perou CM, Hayes DN, Gibbs R, Marra M, Mills GB, Lander E, Spellman P, Wilson R, Sander C, Weinstein J, Meyerson M, Gabriel S, Laird PW, Haussler D, Getz G, Chin L, Network TR. The somatic genomic landscape of glioblastoma. Cell. 2013;155(2):462–77.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Li X, Wu C, Chen N, Gu H, Yen A, Cao L, Wang E, Wang L. PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma. Oncotarget. 2016;7(22):33440–50.

    PubMed  PubMed Central  Google Scholar 

  67. Wei LH, Su H, Hildebrandt IJ, Phelps ME, Czernin J, Weber WA. Changes in tumor metabolism as readout for mammalian target of rapamycin kinase inhibition by rapamycin in glioblastoma. Clin Cancer Res. 2008;14(11):3416–26.

    Article  CAS  PubMed  Google Scholar 

  68. Arcella A, Biagioni F, Antonietta Oliva M, Bucci D, Frati A, Esposito V, Cantore G, Giangaspero F, Fornai F. Rapamycin inhibits the growth of glioblastoma. Brain Res. 2013;1495:37–51.

    Article  CAS  PubMed  Google Scholar 

  69. Eshleman JS, Carlson BL, Mladek AC, Kastner BD, Shide KL, Sarkaria JN. Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy. Cancer Res. 2002;62(24):7291–7.

    CAS  PubMed  Google Scholar 

  70. Lal A, Glazer CA, Martinson HM, Friedman HS, Archer GE, Sampson JH, Riggins GJ. Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. Cancer Res. 2002;62(12):3335–9.

    CAS  PubMed  Google Scholar 

  71. O’Halloran PJ, Viel T, Murray DW, Wachsmuth L, Schwegmann K, Wagner S, Kopka K, Jarzabek MA, Dicker P, Hermann S, Faber C, Klasen T, Schäfers M, O’Brien D, Prehn JH, Jacobs AH, Byrne AT. Mechanistic interrogation of combination bevacizumab/dual PI3K/mTOR inhibitor response in glioblastoma implementing novel MR and PET imaging biomarkers. Eur J Nucl Med Mol Imaging. 2016;43(9):1673–83.

    Article  PubMed  Google Scholar 

  72. Iwanami A, Gini B, Zanca C, Matsutani T, Assuncao A, Nael A, Dang J, Yang H, Zhu S, Kohyama J, Kitabayashi I, Cavenee WK, Cloughesy TF, Furnari FB, Nakamura M, Toyama Y, Okano H, Mischel PS. PML mediates glioblastoma resistance to mammalian target of rapamycin (mTOR)-targeted therapies. Proc Natl Acad Sci U S A. 2013;110(11):4339–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Hatanpaa KJ, Burma S, Zhao D, Habib AA. Epidermal growth factor receptor in glioma: signal transduction, neuropathology, imaging, and radioresistance. Neoplasia. 2010;12(9):675–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Murat A, Migliavacca E, Gorlia T, Lambiv WL, Shay T, Hamou MF, de Tribolet N, Regli L, Wick W, Kouwenhoven MC, Hainfellner JA, Heppner FL, Dietrich PY, Zimmer Y, Cairncross JG, Janzer RC, Domany E, Delorenzi M, Stupp R, Hegi ME. Stem cell-related “self-renewal” signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol. 2008;26(18):3015–24.

    Article  CAS  PubMed  Google Scholar 

  75. Raizer JJ, Abrey LE, Lassman AB, Chang SM, Lamborn KR, Kuhn JG, Yung WK, Gilbert MR, Aldape KA, Wen PY, Fine HA, Mehta M, Deangelis LM, Lieberman F, Cloughesy TF, Robins HI, Dancey J, Prados MD; North American Brain Tumor Consortium. A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro Oncol. (2010);12(1):95–103.

    Google Scholar 

  76. Uhm JH, Ballman KV, Wu W, Giannini C, Krauss JC, Buckner JC, James CD, Scheithauer BW, Behrens RJ, Flynn PJ, Schaefer PL, Dakhill SR, Jaeckle KA. Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074. Int J Radiat Oncol Biol Phys. 2011;80(2):347–53.

    Article  CAS  PubMed  Google Scholar 

  77. Franceschi E, Cavallo G, Lonardi S, Magrini E, Tosoni A, Grosso D, Scopece L, Blatt V, Urbini B, Pession A, Tallini G, Crino L, Brandes AA. Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Br J Cancer. 2007;96(7):1047–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Wehrenberg-Klee E, Redjal N, Leece A, Turker NS, Heidari P, Shah K, Mahmood U. PET imaging of glioblastoma multiforme EGFR expression for therapeutic decision guidance. Am J Nucl Med Mol Imaging. 2015;5(4):379–89.

    CAS  PubMed  PubMed Central  Google Scholar 

  79. Slobbe P, Windhorst AD, Stigter-van Walsum M, Schuit RC, Smit EF, Niessen HG, Solca F, Stehle G, van Dongen GA, Poot AJ. Development of [18F]afatinib as new TKI-PET tracer for EGFR positive tumors. Nucl Med Biol. 2014;41(9):749–57.

    Article  CAS  PubMed  Google Scholar 

  80. Kriete A, Papazoglou E, Edrissi B, Pais H, Pourrezaei K. Automated quantification of quantum-dot-labelled epidermal growth factor receptor internalization via multiscale image segmentation. J Microsc. 2006;222(Pt 1):22–7.

    Article  CAS  PubMed  Google Scholar 

  81. Jarzabek MA, Amberger-Murphy V, Callanan JJ, Gao C, Zagozdzon AM, Shiels L, Wang J, Ligon KL, Rich BE, Dicker P, Gallagher WM, Prehn JH, Byrne AT. Interrogation of gossypol therapy in glioblastoma implementing cell line and patient-derived tumour models. Br J Cancer. 2014;111(12):2275–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Zakaria Z, Tivnan A, Flanagan L, Murray DW, Salvucci M, Stringer BW, Day BW, Boyd AW, Kogel D, Rehm M, O’Brien DF, Byrne AT, Prehn JH. Patient-derived glioblastoma cells show significant heterogeneity in treatment responses to the inhibitor-of-apoptosis-protein antagonist birinapant. Br J Cancer. 2016;114(2):188–98.

    Article  CAS  PubMed  Google Scholar 

  83. Reardon DA, Freeman G, Wu C, Chiocca EA, Wucherpfennig KW, Wen PY, Fritsch EF, Curry Jr WT, Sampson JH, Dranoff G. Immunotherapy advances for glioblastoma. Neuro Oncol. 2014;16(11):1441–58.

    Article  PubMed  PubMed Central  Google Scholar 

  84. Bloch O, Crane CA, Kaur R, Safaee M, Rutkowski MJ, Parsa AT. Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages. Clin Cancer Res. 2013;19(12):3165–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Krummel MF, Sullivan TJ, Allison JP. Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo. Int Immunol. 1996;8(4):519–23.

    Article  CAS  PubMed  Google Scholar 

  86. Bouffet E, Larouche V, Campbell BB, Merico D, de Borja R, Aronson M, Durno C, Krueger J, Cabric V, Ramaswamy V, Zhukova N, Mason G, Farah R, Afzal S, Yalon M, Rechavi G, Magimairajan V, Walsh MF, Constantini S, Dvir R, Elhasid R, Reddy A, Osborn M, Sullivan M, Hansford J, Dodgshun A, Klauber-Demore N, Peterson L, Patel S, Lindhorst S, Atkinson J, Cohen Z, Laframboise R, Dirks P, Taylor M, Malkin D, Albrecht S, Dudley RW, Jabado N, Hawkins CE, Shlien A, Tabori U. Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency. J Clin Oncol. 2016.

    Google Scholar 

  87. Philips GK, Atkins M. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies. Int Immunol. 2015;27(1):39–46.

    Article  CAS  PubMed  Google Scholar 

  88. DeVincenzo J, Lambkin-Williams R, Wilkinson T, Cehelsky J, Nochur S, Walsh E, Meyers R, Gollob J, Vaishnaw A. A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc Natl Acad Sci U S A. 2010;107(19):8800–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. Ahmed N, Fessi H, Elaissari A. Theranostic applications of nanoparticles in cancer. Drug Discov Today. 2012;17(17-18):928–34. doi:10.1016/j.drudis.2012.03.010.

    Article  CAS  PubMed  Google Scholar 

  90. Penet M, Zhihang C, Samata K, Pomper M, Bhujwalla ZM. Theranostic imaging of cancer. Eur J Radiol. 2012;81:S124–6. doi:10.1097/MPG.0b013e3181a15ae8.Screening.

    Article  PubMed  PubMed Central  Google Scholar 

  91. Karim R, Palazzo C, Evrard B, Piel G. Nanocarriers for the treatment of glioblastoma multiforme: current state-of-the-art. J Control Release. 2016;227:23–37. doi:10.1016/j.jconrel.2016.02.026.

    Article  CAS  PubMed  Google Scholar 

  92. Xie J, Lee S, Chen X. Nanoparticle-based theranostic agents. Adv Drug Deliv Rev. 2010;62:1064–79. doi:10.1016/j.addr.2010.07.009.Nanoparticle-based.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Zhong Y, Wang C, Cheng R, Cheng L, Meng F, Liu Z, Zhong Z. CRGD-directed, NIR-responsive and robust AuNR/PEG-PCL hybrid nanoparticles for targeted chemotherapy of glioblastoma in vivo. J Control Release. 2014;195:63–71. doi:10.1016/j.jconrel.2014.07.054.

    Article  CAS  PubMed  Google Scholar 

  94. Fang J, Nakamura H, Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev. 2011;63(3):136–51. doi:10.1016/j.addr.2010.04.009.

    Article  CAS  PubMed  Google Scholar 

  95. Ferrari C, Asabella AN, Villano C, Giacobbi B, Coccetti D, Panichelli P, Rubini G. Copper-64 dichloride as theranostic agent for glioblastoma multiforme: a preclinical study. Biomed Res Int. 2015;2015:129764. doi:10.1155/2015/129764.

    Article  PubMed  PubMed Central  Google Scholar 

  96. Yang H, Oh BC, Kim JH, Ahn T, Nam H, Park CW, Kim J. Multifunctional poly(aspartic acid) nanoparticles containing iron oxide nanocrystals and doxorubicin for simultaneous cancer diagnosis and therapy. Colloids Surf A Physicochem Eng Asp. 2011;391(1-3):208–15. doi:10.1016/j.colsurfa.2011.04.032.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre for Systems Medicine, Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland, Dublin, Ireland

    Kate Connor, Monika A. Jarzabek, Kieron White & Annette T. Byrne

  2. European Institute for Molecular Imaging (EIMI), Westfalian Wilhelms University (WWU) Münster, Münster, Germany

    Andreas H. Jacobs

  3. Department of Geriatrics and Neurology, Johanniter Hospital, Bonn, Germany

    Andreas H. Jacobs

Authors
  1. Kate Connor
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Monika A. Jarzabek
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kieron White
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Andreas H. Jacobs
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Annette T. Byrne
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Annette T. Byrne .

Editor information

Editors and Affiliations

  1. Centre for Systems Medicine, Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland, Dublin, Ireland

    Amanda Tivnan

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing AG

About this chapter

Cite this chapter

Connor, K., Jarzabek, M.A., White, K., Jacobs, A.H., Byrne, A.T. (2016). Imaging Targeted Therapy Response and Resistance in Glioblastoma. In: Tivnan, A. (eds) Resistance to Targeted Therapies Against Adult Brain Cancers. Resistance to Targeted Anti-Cancer Therapeutics. Springer, Cham. https://doi.org/10.1007/978-3-319-46505-0_8

Download citation

Publish with us

Policies and ethics

Search

Navigation